FABP6
FABP6 Molecule Information
Name:Bile acid binding protein
Target Synonym:ILLBP;Intestinal 15 kDa protein;I-BABP;FABP6;Fatty acid-binding protein 6;GT;ILBP;I-15P;Intestinal bile acid-binding protein
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Approved
FABP6 Molecule Synonym Name
FABP6,ILBP,ILLBP,Gastrotropin,GT,I-15P,I-BABP,I-BALB,I-BAP
FABP6 Molecule Background
Fatty acid-binding protein 6 (FABP6), is also known as Intestinal bile acid-binding protein (I-BABP), Ileal lipid-binding protein (ILBP), Intestinal 15 kDa protein (I-15P), Gastrotropin (GT). FABP6 is a cytoplasm protein which belongs to the calycin superfamily and fatty-acid binding protein (FABP) family. Isoform 2 of FABP6 is expressed in colorectal adenocarcinomas and their adjacent normal mucosa (at protein level). Isoform 1 of FABP6 is expressed in the jejunum, ileum, cecum and ascending colon intestine. Ileal protein FABP6 stimulates gastric acid and pepsinogen secretion. FABP6 seems to be able to bind to bile salts and bilirubins. Isoform 2 of FABP6 is essential for the survival of colon cancer cells to bile acid-induced apoptosis.
FABP6 References
FABP6 Public Drug Information
Name |
Research Code |
Research Phase |
Company |
First Brand Name |
First Approved Country |
First Indication |
First Approved Company |
First Approved Date |
Indications |
Clinical Trials |
Colesevelam Hydrochloride |
GT31-104; GT31-104HB; GT-31104 |
Approved |
Genzyme, Daiichi Sankyo |
WELCHOL |
fda |
Heterozygous familial hypercholesterolemia, Type 2 diabetes, Primary hyperlipidemia |
DAIICHI SANKYO |
2000-05-26 |
Heterozygous familial hypercholesterolemia, Hyperlipoproteinaemia type IIa, Type 2 diabetes, Primary hypercholesterolemia, Primary hyperlipidemia, Hypercholesterolemia, Familial hypercholesterolemia |
Details
|
Colestipol Hydrochloride |
|
Approved |
Pfizer |
COLESTID |
fda |
|
PHARMACIA UPJOHN |
1977-04-04 |
Hyperlipidemia |
Details
|
FABP6 Clinical Drug Information
Name |
Research Code |
Research Phase |
Company |
Indications |
Clinical Trials |
SKF-97426 |
SKF-97426; SKF-97426A |
Phase Ⅱ |
GlaxoSmithKline |
Hypercholesterolemia |
Details
|
HBS-107 |
HBS-107 |
Phase Ⅱ |
Hisamitsu Pharmaceutical |
Hypercholesterolemia |
Details
|
Colesevelam (Ironwood) |
IW-3718 |
Phase Ⅲ |
Ironwood |
Gastroesophageal reflux disease (GERD) |
Details
|
GT-102279 |
GT102-279; GT-102-279; GT-102279 |
Phase Ⅱ |
Genzyme |
Hypercholesterolemia |
Details
|
BTG-511 |
BTG-511 |
Phase Ⅱ |
BTG plc |
Hypercholesterolemia |
Details
|
A-3384 |
A-3384 |
Phase Ⅱ |
Albireo |
Bile acid malabsorption (BAM) |
Details
|